Seth J. Frantzman | Stories - Washington Times
Read the latest stories and columns from staff writer Seth J. Frantzman in The Washington Times.
Stay updated with breaking news from Published December. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Read the latest stories and columns from staff writer Seth J. Frantzman in The Washington Times.
Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.
With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.
From the prospect of semaglutide and MDMA for substance use disorder to evolving research around personality disorders and OCD, here are 5 key topics from the annual psychiatric meeting.
Lykos Therapeutics' new drug application for MDMA plus psychiatric intervention for adults with PTSD will be the first reviewed by an FDA committee for such a therapy.